Since the treatment of lung squamous cell carcinoma (SCC) was limited due to a lack of appropriate biomarkers and novel target agents. Immune checkpoint inhibitors can offer an effective treatment for patients with advanced non-small cell lung cancer. Here, we described the cases of two patients with SCC who showed a good response following treatment with tislelizumab. We encountered two patients with unresectable lung SCC who were treated with immunotherapy and chemotherapy. One patient had negatively programmed death-ligand 1 expression, and the primary lesion becomes a thick wall cavity after the tislelizumab combined with chemotherapy. Another patient was diagnosed with advanced lung SCC with negative programmed death-ligand 1 expression. After the treatment, the fluorine-18-fluorodeoxyglucose PET/computed tomography indicated that no abnormal increase in radioactivity uptake and tend to complete remission. We found a significant response or even complete response in unresectable SCC treated with tislelizumab combined with chemotherapy. Our cases added evidence of the feasibility and efficacy of tislelizumab combined with chemotherapy in unresectable lung SCC.

中文翻译：

---

无论程序性死亡配体 1 表达如何，用替雷利珠单抗成功治疗两名不可切除的肺鳞状细胞癌患者：两例报告。

由于缺乏适当的生物标志物和新型靶向药物，肺鳞状细胞癌（SCC）的治疗受到限制。免疫检查点抑制剂可以为晚期非小细胞肺癌患者提供有效的治疗。在这里，我们描述了两名鳞状细胞癌患者的病例，他们在接受替雷利珠单抗治疗后表现出良好的反应。我们遇到了两名无法切除的肺鳞状细胞癌患者，他们接受了免疫疗法和化疗。1例患者出现程序性死亡配体1负表达，替雷利珠单抗联合化疗后原发病灶变为厚壁空洞。另一名患者被诊断为晚期肺鳞状细胞癌，程序性死亡配体 1 表达呈阴性。治疗后，氟18-氟脱氧葡萄糖PET/计算机断层扫描显示放射性摄取未见异常增加，并趋于完全缓解。我们发现替雷利珠单抗联合化疗治疗不可切除的鳞状细胞癌有显着缓解甚至完全缓解。我们的病例进一步证明了替雷利珠单抗联合化疗治疗不可切除的肺 SCC 的可行性和有效性。